HONG KONG – China biopharmaceutical firm Zai Lab Ltd. bagged marketing approval from Hong Kong's Department of Health this week for its PARP inhibitor, Zejula (niraparib), targeting patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian cancer. It is intended for second-line maintenance use for adult ovarian cancer patients.